293 related articles for article (PubMed ID: 34150658)
1. Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer.
Bae SJ; Kim JH; Ahn SG; Jeung HC; Sohn J; Kim GM; Kim MH; Kim SI; Park S; Park HS; Kim JY; Jeong J
Front Oncol; 2021; 11():689587. PubMed ID: 34150658
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of biosimilar trastuzumab MYL-1401O in HER2-positive breast cancer.
Eser K; Sezer E; Erçolak V; İnal A
Am J Manag Care; 2023 Feb; 29(2):e36-e42. PubMed ID: 36811986
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.
Bernat-Peguera A; Trigueros M; Ferrando-Díez A; Ibáñez C; Bystrup S; Martínez-Cardús A; Margelí M; Martínez-Balibrea E
Breast; 2022 Apr; 62():1-9. PubMed ID: 35078146
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre.
Matovina S; Engler T; Volmer LL; Müller H; Grischke EM; Staebler A; Hahn M; Brucker SY; Hartkopf AD
Geburtshilfe Frauenheilkd; 2023 Jun; 83(6):694-701. PubMed ID: 37614685
[No Abstract] [Full Text] [Related]
6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Stebbing J; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Pikiel J; Eniu AE; Li RK; Tiangco B; Lee SJ; Kim S
Breast Cancer Res Treat; 2021 Aug; 188(3):631-640. PubMed ID: 34148205
[TBL] [Abstract][Full Text] [Related]
8. Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.
Lee YP; Lee MS; Kim H; Kim JY; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2022 Oct; 54(4):1130-1137. PubMed ID: 35038825
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China.
Qian Y; Peng Y; Zhou H; Zhang L; Yuan Y
Ann Transl Med; 2022 Aug; 10(16):877. PubMed ID: 36111041
[TBL] [Abstract][Full Text] [Related]
10. First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.
Celik A; Berg T; Nielsen LB; Jensen MB; Ejlertsen B; Knoop A; Andersson M
Breast Cancer (Auckl); 2022; 16():11782234221086992. PubMed ID: 35359608
[TBL] [Abstract][Full Text] [Related]
11. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Esteva FJ; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskiy D; Pikiel J; Eniu AE; Li RK; Rusyn AV; Tiangco B; Lee SJ; Lee SY; Yu SY; Stebbing J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):839-847. PubMed ID: 31428820
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.
Zhang R; Liu X; Song G; Zhang Y; Li H
Cancer Res Treat; 2023 Dec; ():. PubMed ID: 38147816
[TBL] [Abstract][Full Text] [Related]
14. Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Stebbing J; Baranau Y; Baryash V; Moiseyenko V; Boliukh D; Antone N; Manikhas A; Chornobai A; Park T; Baek EH; Lee J; Choi J; Kim N; Ahn K; Lee SJ; Kim S
BioDrugs; 2023 May; 37(3):433-440. PubMed ID: 36881323
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
18. Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence.
de Pinho IS; Luz P; Alves L; Lopes-Brás R; Patel V; Esperança-Martins M; Gonçalves L; Freitas R; Simão D; Galnares MR; Fernandes I; Criado SA; Casado SG; Cañada JB; Vega IMS; Costa JG; Fernandes AS; de Sousa RT; Costa L
Clin Drug Investig; 2023 Sep; 43(9):691-698. PubMed ID: 37479867
[TBL] [Abstract][Full Text] [Related]
19. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
